Optos plc (LSE: OPTS), a leading medical retinal imaging company, provides an update on current trading in advance of its interim results announcement on 16th May 2013.
Publications on european-business
Optos plc (LSE: OPTS), a world leader in retinal imaging, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Microperimetry as part of the OptosOCT SLO. Microperimetry assesses retinal sensitivity providing a precise correlation between structural pathology and corresponding visual functional defects. This data provides more clinical information to support the evaluation of patients’ vision.
If you have ever had your retina checked, you know what a ‘pleasure’ it can be: The eye doctor uses drops to dilate your pupils, then shines a shockingly bright light into your eye to conduct the examination. Hours later you are still unable to read, drive or be in sunlight. Many eye care professionals offer an alternative to dilation using new equipment from Optos. Supported by extensive clinical evidence, strategic acquisitions and new office locations, Optos is building the retina company and expanding the global reach of its diagnostic and treatment technologies.